Antares Pharma Inc represents a set of key values and a strong corporate philosophy. With a focus on innovation, Antares Pharma Inc strives to develop and commercialize pharmaceutical products that improve patients' lives. The company places great importance on quality, aiming to deliver safe and effective treatments. Antares Pharma Inc is committed to fostering a culture of integrity and ethical business practices, ensuring transparency and accountability in all its operations. By prioritizing customer needs and collaboration, Antares Pharma Inc aims to drive shareholder value and establish itself as a leader in the pharmaceutical industry.

Antares Pharma Inc is primarily present in the United States.

Antares Pharma Inc has achieved significant milestones throughout its years of operation. Notably, the company received FDA approval for its flagship product, the Otrexup™ self-injection device, a breakthrough treatment for patients with rheumatoid arthritis and psoriasis. Antares also secured licensing agreements with leading pharmaceutical companies, including Teva and AMAG, further extending its market reach. In addition, the company successfully launched the Makena® subcutaneous auto injector, enhancing patient convenience for a hormone therapy drug used in high-risk pregnancies. Antares Pharma Inc continues to innovate, pursue strategic collaborations, and make remarkable progress in delivering advanced pharmaceutical solutions.

Antares Pharma Inc. is a biopharmaceutical company specializing in the development and commercialization of self-administered parenteral pharmaceutical products. Founded in 1979, Antares Pharma has a rich history of innovation and scientific expertise. The company focuses on advanced drug delivery technologies, including its proprietary needle-free injection system, to improve patient convenience and adherence. With a strong commitment to research and development, Antares Pharma has successfully brought several products to market and licenses its technologies to pharmaceutical partners worldwide. The company's dedication to improving therapeutic outcomes has earned it a reputable position in the pharmaceutical industry.

The main competitors of Antares Pharma Inc in the market are pharmaceutical companies such as Eli Lilly and Company, Novartis AG, Pfizer Inc, Johnson & Johnson, and Amgen Inc.

Antares Pharma Inc is primarily active in the pharmaceutical industry.

Antares Pharma Inc is a pharmaceutical company that specializes in developing and commercializing self-injection drug delivery systems. Their business model focuses on developing innovative technologies that improve the convenience, safety, and efficacy of medication administration. Antares Pharma Inc partners with pharmaceutical companies to enhance their existing products or develop new drug formulations. By providing a range of self-injection systems such as autoinjectors and pen injectors, Antares Pharma Inc aims to improve patient adherence to medication regimens and enhance the overall treatment experience. They prioritize patient-centric solutions to meet the evolving needs of the pharmaceutical industry.

مُعامل القيمة السوقية إلى الأرباح لـ Antares Pharma هو ١٦٫٥٨.

مُعامِل القيمة إلى المبيعات Antares Pharma هو ٣٫٢٢.

نقاط جودة AlleAktien لـ Antares Pharma هي 5/10.

المتوقعة Antares Pharma الإيرادات هي ٣٠٣٫٤٦ مليون. USD.

صافي الربح المتوقعة Antares Pharma هو ٥٨٫٩٠ مليون. USD.

Antares Pharma Inc is a company that specializes in the development, manufacturing, and marketing of medications, particularly injection solutions. The company has three main business areas: 1. Marketing and manufacturing of medications: Antares Pharma produces and markets primarily injection solutions for various applications. The company has several leading products, including the legal opioid Vergentanib, hormone injections for women, disposable insulin pens, and more. 2. Research and development: Antares Pharma is dedicated to advancing the development of new medications and injection systems. The company heavily invests in research and development to create innovative products that meet the needs of patients. 3. Licensing and partnerships: Antares Pharma also collaborates with other pharmaceutical companies to distribute its products worldwide. The company has partnerships with companies such as Teva, Ferring, and Pfizer to globally market its products. The company offers several leading products: 1. Vergentanib: Vergentanib is a legal opioid for pain relief. The medication is administered through a pre-filled syringe pen manufactured by Antares Pharma. Vergentanib is a widely approved medication available in many countries worldwide. 2. OTREXUP: OTREXUP is a disposable insulin pen for the treatment of diabetes. The insulin pen is made from a special material that reduces the risk of overdosing. 3. QuickShot: QuickShot is a disposable injection system for hormone injections for women. The system is convenient and easy to use, and is utilized by many women around the world. Antares Pharma's business model is based on the development and marketing of injection products for various applications. The company invests in research and development to create innovative products that meet the needs of patients. Antares Pharma also collaborates with partners to market its products worldwide. The company has a strong presence in the market and strives to continue developing and distributing top-quality products to assist patients.

يوزع Antares Pharma أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Antares Pharma في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـAntares Pharma هو US0366421065.

رمز WKN لـ Antares Pharma هو 903128.

الرمز المُختصر لـ Antares Pharma هو ATRS.

خلال آخر 12 شهراً، دفعت Antares Pharma توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Antares Pharma خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Antares Pharma هي .

Antares Pharma يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Antares Pharma دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Antares Pharma يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Antares Pharma المُعلن عنها في ٢٩‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٩‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٩‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Antares Pharma 0 USD كأرباح أسهم.

يتم توزيع أرباح Antares Pharma بالعملة USD.